for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inovio Pharmaceuticals Inc

INO.O

Latest Trade

9.00USD

Change

-0.10(-1.10%)

Volume

13,490,109

Today's Range

8.81

 - 

9.30

52 Week Range

3.14

 - 

33.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.10
Open
9.00
Volume
13,490,109
3M AVG Volume
227.62
Today's High
9.30
Today's Low
8.81
52 Week High
33.79
52 Week Low
3.14
Shares Out (MIL)
186.85
Market Cap (MIL)
1,681.66
Forward P/E
-7.68
Dividend (Yield %)
--

Next Event

Inovio Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Inovio Says Public Offering Of 17.7 Mln Common Shares At Price Of $8.5/Shr

Inovio Pharmaceuticals - Preliminarily Estimates Cash, Equivalents & Short-Term Investments As Of Dec 31, 2020 Of About $412 Mln

Inovio's VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment Of Precancerous Vulvar Dysplasia Caused By HPV-16/18

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry

Biotechnology & Drugs

Contact Info

6769 Mesa Ridge Rd

SAN DIEGO, CA

92121-2995

United States

+1.858.4103134

http://www.inovio.com/

Executive Leadership

Simon X. Benito

Independent Chairman of the Board

Jong Joseph Kim

President, Chief Executive Officer, Director

Peter D. Kies

Chief Financial Officer

Jacqueline Elizabeth Elizabeth Shea

Chief Operating Officer

Laurent M Humeau

Chief Scientific Officer

Key Stats

2.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.080

2018

-1.050

2019

-1.210

2020(E)

-1.173
Price To Earnings (TTM)
--
Price To Sales (TTM)
796.95
Price To Book (MRQ)
4.65
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
16.58
LT Debt To Equity (MRQ)
16.58
Return on Investment (TTM)
-67.92
Return on Equity (TTM)
-60.62

Latest News

Latest News

Inovio expects to begin late-stage COVID-19 vaccine study in second quarter

Inovio Pharmaceuticals Inc expects to start a late-stage U.S. study of its experimental COVID-19 vaccine candidate in the second quarter of 2021, the drug developer's chief executive officer said on Monday.

Inovio partners with Advaccine to commercialize COVID-19 vaccine in China

Inovio Pharmaceuticals Inc has partnered with Advaccine Biopharmaceuticals Suzhou Co Ltd to manufacture and commercialize its COVID-19 vaccine candidate in China, the companies said on Monday.

Inovio doses first volunteer as part of its COVID-19 vaccine mid-stage trial

Inovio Pharmaceuticals Inc said on Monday it has dosed the first participant in a mid-stage clinical trial testing its COVID-19 vaccine candidate, INO-4800.

Inovio doses first participant of COVID-19 vaccine mid-stage trial

Inovio Pharmaceuticals Inc said on Monday it has dosed the first participant in a mid-stage clinical trial testing its COVID-19 vaccine candidate, INO-4800.

Inovio signs COVID-19 vaccine manufacturing deal with Japan's Kaneka

Japan's Kaneka Corp has entered into a deal to manufacture Inovio Pharmaceuticals Inc's COVID-19 vaccine candidate, the U.S.-based vaccine maker said on Thursday.

Inovio to begin mid-stage study of COVID-19 vaccine candidate

Inovio Pharmaceuticals Inc <INO.O> has received U.S. health regulator's clearance to begin a mid-stage study of its COVID-19 vaccine candidate, the vaccine maker said on Monday.

Inovio to begin mid-stage study of COVID-19 vaccine candidate

Inovio Pharmaceuticals Inc said on Monday it had received the U.S. health regulator's clearance to begin a mid-stage study of its COVID-19 vaccine candidate, INO-4800.

Inovio expects FDA decision on COVID-19 vaccine trial start this month

Inovio Pharmaceuticals Inc on Monday said it expects the U.S. Food and Drug Administration to decide this month whether to allow an advanced trial of the company's experimental COVID-19 vaccine to move forward.

Inovio says expects FDA decision on COVID vaccine trial this month

Inovio Pharmaceuticals Inc on Monday said it expects the U.S. Food and Drug Administration to decide this month whether to allow an advanced trial of the company's experimental COVID-19 vaccine to move forward.

FACTBOX-The race for a coronavirus vaccine

More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human trials, according to the World Health Organization (WHO). The following list tracks the latest developments from major drugmakers and research institutes...

U.S. FDA pauses Inovio's coronavirus vaccine trial plan

The U.S. health regulator has put a hold on Inovio Pharmaceuticals Inc's <INO.O> plans to start final trials of its coronavirus vaccine as the agency seeks more information, including details on a delivery device used to inject genetic material into cells.

Inovio's potential COVID-19 vaccine trial on partial clinical hold

Inovio Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration had placed a partial clinical hold on the company's planned mid-to-late-stage trial of its experimental coronavirus vaccine candidate.

Inovio partners with Thermo Fisher to bolster COVID-19 vaccine supply

Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture the drug developer's experimental coronavirus vaccine, as it looks to boost the supply ahead of large trials this month.

Inovio bolsters COVID-19 vaccine supply with Thermo Fisher deal

Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture its experimental coronavirus vaccine to boost the supply of the vaccine.

BRIEF-Inovio Says COVID-19 Vaccine Candidate To Enter Phase 2/3 Study In Sept - Conf Call

* INOVIO PHARMACEUTICALS SAYS COVID-19 VACCINE CANDIDATE TO ENTER PHASE 2/3 STUDY IN SEPTEMBER - CONF CALL

Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in September

Inovio Pharmaceuticals Inc expects its experimental COVID-19 vaccine to enter mid-to-late stage study in September and secure U.S. emergency use authorization sometime in 2021, the U.S. vaccine developer said on Monday.

Inovio vaccine candidate shows promise in non-human study

Inovio Pharmaceuticals Inc said on Thursday its COVID-19 vaccine candidate was effective in protecting rhesus macaques from the virus 13 weeks after the last vaccination.

Inovio vaccine candidate shows promise in non-human study

Inovio Pharmaceuticals Inc said on Thursday its coronavirus vaccine candidate was effective in protecting rhesus macaques from the virus 13 weeks after the last vaccination, sending its shares up 20% before the bell.

Inovio's COVID-19 vaccine candidate shows promise in small early-stage trial

An experimental coronavirus vaccine developed by Inovio Pharmaceuticals Inc <INO.O> showed promise and was found to be safe in an early-stage human trial, the company said on Tuesday.

Inovio's COVID-19 vaccine candidate shows promise in early-stage trial

Inovio Pharmaceuticals Inc on Tuesday reported positive interim data from an early-stage study assessing its potential COVID-19 vaccine wherein patients showed immune response and was deemed safe. (https://reut.rs/2NFcNqL) (Reporting by Trisha Roy in Bengaluru; Editing by...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up